Abvc Biopharma (ABVC) Cash from Operations (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Cash from Operations came in at -$244413.0 in Q2 2026, up 72.67% on a YoY basis from -$141552.4 in Q2 2025, and up 72.67% quarter-over-quarter from -$894243.0 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Cash from Operations (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Cash from Operations for 17 consecutive years, with -$244413.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Operations rose 72.67% year-over-year to -$244413.0; the trailing twelve-month figure through Jun 2026 stood at -$2.7 million (down 29.63% YoY), and the FY2025 full-year result was -$3.0 million, down 65.07% from the prior year.
- Cash from Operations climbed to -$244413.0 in Q2 2026 per ABVC's latest filing, from -$894243.0 in the prior quarter.
- Across five years, Cash from Operations topped out at $60230.0 in Q3 2024 and bottomed at -$3.4 million in Q2 2022.
- Historically, Cash from Operations has averaged -$973296.6 across 5 years, with a median of -$798154.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations surged 104.43% in 2024, then sank 1701.71% in 2025.
- Over 5 years, Cash from Operations stood at -$461069.0 in 2022, then grew by 6.64% to -$430463.0 in 2023, then tumbled by 63.11% to -$702134.0 in 2024, then rose by 16.31% to -$587582.0 in 2025, then jumped by 58.4% to -$244413.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered -$244413.0, -$894243.0, and -$587582.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -244,413.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -244,413.00 |
| Mar 31, 2026 | -894,243.00 |
| Dec 31, 2025 | -587,582.00 |
| Sep 30, 2025 | -964,710.00 |
| Jun 30, 2025 | -894,174.00 |
| Mar 31, 2025 | -539,833.00 |
| Dec 31, 2024 | -702,134.00 |
| Sep 30, 2024 | 60,230.00 |
| Jun 30, 2024 | -211,425.00 |
| Mar 31, 2024 | -955,816.00 |
| Dec 31, 2023 | -430,463.00 |
| Sep 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -899,827.00 |
| Mar 31, 2023 | -1.50 Mn |
| Dec 31, 2022 | -461,069.00 |
| Sep 30, 2022 | -513,704.00 |
| Jun 30, 2022 | -3.43 Mn |
| Mar 31, 2022 | -2.99 Mn |
| Dec 31, 2021 | -2.52 Mn |
| Sep 30, 2021 | -2.22 Mn |